Use of anti-HER2 antibody-drug conjugates in treatment of cancer
By developing anti-HER2 antibody-drug conjugates, the treatment of anti-HER2 drug resistance in the prior art is solved by the treatment of insensitive or drug-resistant HER2-positive and low-expressive breast cancer patients with insensitivity or drug resistance. and the problem of ineffective treatment in patients with low expression achieved significant anti-tumor effects.
Patent Information
- Application Number
- CN202411206168.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-05-11
- Filing Date
- 2019-04-30
- Publication Date
- 2024-12-03
AI Technical Summary
Existing anti-HER2 antibody drugs such as trastuzumab and T-DM1 have drug resistance problems in the treatment of HER2-positive breast cancer patients, especially in patients with low HER2 expression, which are ineffective in treating these drugs, and are inherently resistant and obtained. Sexual resistance is relatively common, resulting in unsatisfactory treatment results.
Provide an anti-HER2 antibody-drug conjugate that forms a new conjugate by removing part of the amino group in the antibody for the treatment of insensitive or ineffective cancers, including breast and gastric cancers, Especially for patients with insensitivity or drug resistance to trastuzumab and T-DM1 treatment. This conjugate improves therapeutic efficacy by coupling an antibody targeting HER2 to a cytotoxic drug.
In the experiment, the new antibody-drug conjugates significantly inhibited the growth of HER2-positive and low-expressing breast cancer, which was better than the therapeutic effect of T-DM1, and was used to trastuzumab-resistant cell lines and HER2-low-expressing cell lines. All showed significant anti-tumor efficacy and no obvious toxicity, providing a potential treatment option for patients with drug resistance and low expression.
Smart Images

Figure CN119055787A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application No. 201980018635.5, filed on April 30, 2019, with the invention name “Use of anti-HER2 antibody-drug conjugates in the treatment of cancer”. Field of the Invention
[0002] The present invention belongs to the field of biomedicine technology. Specifically, the present invention relates to the use of anti-HER2 antibody-drug conjugates in treating cancer. Background of the Invention
[0004] As a new type of targeted therapy drug, antibody-drug conjugate (ADC) has created a new era of tumor treatment. Under the leadership of Seattle Genetics, Inc. and ImmunoGen, Inc., many multinational pharmaceutical companies and start-ups have carried out research and development in this field. According to Market Research, there are 45 such candidate drugs in clinical research worldwide.
[0005] ADC uses the targeting properties of antibodies to "precisely" deliver the drugs connected to them to target cells, thereby effectively increasing the drug concentration in the local lesion, while greatly reducing the drug concentration in other tissues and organs in the body, thereby achieving efficacy enhancement and toxicity reduction. Both polyclonal antibodies and monoclonal antibodies used for these strategies have been reported (Rowland et al., 1986, Cancer Immunol. Immunother., 21: 183-87). Most of the antibodies in ADCs currently used clinically are humanized antibodies, for example, PSMA ADC (anti-PSMA antibody-MMAE conjugate), SGN-75 (anti-CD70 antibody-MMAF conjugate), and T-DM1 (trastuzumab-DM1 conjugate) are all humanized antibodies. Currently FDA-approved ADC drugs include (T-DM1), (Gemtuzumab ozogamicin), (inotuzumab ozogamicin) and SGN-35.
[0006] Clinically, anti-HER2 antibody drug trastuzumab is used to treat breast cancer with high expression of HER2. In clinical trials, 15% of breast cancer patients with immunohistochemistry (IHC) 2+ or above levels produced clinical responses to trastuzumab, and the median response lasted for 9.1 months (see, for example, Cobleigh et al., 1996, Journal of Clinical Oncology, 14:737-744). Trastuzumab (trade name Herceptin) was approved by the U.S. Food and Drug Administration (FDA) on September 25, 1998 for the treatment of breast cancer patients who overexpress HER2 protein.
[0007] Trastuzumab has become the first-line treatment for HER2-positive breast cancer. Although it has saved some breast cancer patients or prolonged their survival, it is only effective for patients with high HER2 expression (about 15% of clinical breast cancer patients), and has no therapeutic effect on many patients with low HER2 expression. Clinical studies have found that many HER2-positive breast cancer patients are also insensitive to trastuzumab.
[0008] In addition, during trastuzumab treatment, many patients gradually change from drug sensitivity to drug resistance. There may be many mechanisms for drug resistance, such as changes in the molecular structure of HER2 receptors, changes in the PI3K / AKT signaling pathway, or the involvement of immune mechanisms. After trastuzumab drug resistance occurs, the commonly used drug regimen in domestic clinical practice is lapatinib + capecitabine.
[0009] ADC drugs based on trastuzumab and cytotoxic drug DM1 (T-DM1) is approved for HER2-positive metastatic breast cancer that has been previously treated with taxanes and trastuzumab. The NCCN (National Comprehensive Cancer Network) guidelines recommend T-DM1 as the second-line preferred treatment option after trastuzumab treatment failure. Although T-DM1 has achieved impressive clinical efficacy in many patients, both intrinsic resistance and acquired resistance have become challenges (Ríos-Luci C et al., Cancer Res., September 1, 2017, 77(17): 4639-4651). Although HER2-positive metastatic breast cancer seems to have relatively little intrinsic resistance to T-DM1, most patients treated with T-DM1 will develop acquired resistance (Barok M et al., Breast Cancer Res., March 5, 2014, 16(2): 209), suggesting that acquired resistance to T-DM1 is a common problem.
[0010] WO 2017088734 provides an anti-HER2 antibody-drug conjugate, and a comparative study with T-DM1 found that the anti-HER2 antibody-drug conjugate has better therapeutic activity against HER2-positive tumors than T-DM1. However, the document does not study the treatment methods and treatment effects of cancers that are insensitive to HER2 targeted drugs such as trastuzumab or T-DM1 or are ineffective against HER2 targeted drugs such as trastuzumab or T-DM1 (such as HER2-positive cancers with drug resistance or cancers with low HER2 expression). SUMMARY OF THE INVENTION
[0012] The first aspect of the present invention provides a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing for the preparation of a drug for preventing and / or treating cancer that is insensitive to or ineffective against HER2-targeted drug therapy.
[0013]
[0014] in
[0015] A is a group obtained by removing n amino groups from an anti-HER2 antibody or an active fragment or variant thereof, preferably, A is a group obtained by removing n amino groups from trastuzumab or pertuzumab, and
[0016] n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.
[0017] The second aspect of the present invention provides a conjugate of the above formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing, which is used to prevent and / or treat cancers that are insensitive to or ineffective against HER2-targeted drug therapy.
[0018] The third aspect of the present invention provides a method for preventing and / or treating cancer that is insensitive to or ineffective against HER2-targeted drug therapy, the method comprising administering to an individual in need thereof a therapeutically effective amount of a conjugate of the above-mentioned formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Shows the growth changes of tumor volume in each group of mice in the JIMT-1 human breast cancer model.
[0020] Figure 2 Shows the changes in body weight of each group of mice in the JIMT-1 human breast cancer model.
[0021] Figure 3Shows the growth changes of tumor volume in breast cancer xenograft model BR0438 tumor-bearing mice after administration.
[0022] Figure 4 Shows the changes in body weight of BR0438 tumor-bearing mice after administration of the breast cancer tumor xenograft model. DETAILED DESCRIPTION OF THE INVENTION
[0024] Definition of terms
[0025] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art. For relevant definitions and terms, see, for example, Current Protocols in Molecular Biology (Ausubel).
[0026] All documents mentioned herein are incorporated herein by reference in their entirety.
[0027] Herein, HER2 refers to the native sequence human HER2 protein (Genebank Accession No.: X03363, see, e.g., Semba et al., 1985, PNAS, 82:6497-6501; and Yamamoto et al., 1986, Nature, 319:230-234) and its functional derivatives, e.g., amino acid sequence variants.
[0028] The natural sequence HER2 herein can be isolated from nature, or prepared by recombinant DNA technology, chemical synthesis, or a combination thereof.
[0029] As used herein, the term "antibody" is interpreted in the broadest sense and includes intact monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (eg, bispecific antibodies) formed from at least two intact antibodies, so long as they have the desired biological activity.
[0030] As used herein, the term "monoclonal antibody" refers to an antibody that comes from a group of substantially homogeneous antibodies, i.e., the antibodies that make up the group are identical except for a small amount of natural mutations that may be present. Monoclonal antibodies have high specificity for one determinant (epitope) of an antigen, whereas polyclonal antibodies, in contrast, contain different antibodies for different determinants (epitopes). In addition to their specificity, monoclonal antibodies have the advantage that they can be synthesized without contamination by other antibodies. The modifier "monoclonal" here indicates that the antibody is characterized by being from a substantially homogeneous group of antibodies and should not be construed as requiring production by a particular method.
[0031] Herein, monoclonal antibodies also specifically include chimeric antibodies, i.e., a portion of the heavy chain and / or light chain is identical or homologous to a certain type, class or subclass of antibody, and the remaining portion is identical or homologous to another type, class or subclass of antibody, as long as they have the desired biological activity (see, e.g., US 4,816,567; and Morrison et al., 1984, PNAS, 81:6851-6855). Chimeric antibodies that can be used in the present invention include primatized antibodies, which contain variable region antigen binding sequences from non-human primates (e.g., ancient monkeys, orangutans, etc.) and human constant region sequences.
[0032] The term "antibody fragment" refers to a portion of an antibody, preferably the antigen binding region or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; and single-chain antibody molecules.
[0033] The term "bispecific antibody", also known as "bifunctional antibody conjugate", refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) through a coupling arm, which retains the activity of each antibody and thus has bifunctionality and bispecificity.
[0034] The term "multispecific antibody" includes, for example, trispecific antibodies, which are antibodies with three different antigen-binding specificities, and tetraspecific antibodies, which are antibodies with four different antigen-binding specificities.
[0035] The term "complete antibody" refers to an antibody comprising an antigen-binding variable region and a light chain constant region (CL), a heavy chain constant region (CH1, CH2 and CH3). The constant region can be a native sequence (e.g., a human native constant region sequence) or an amino acid sequence variant thereof. A complete antibody is preferably a complete antibody with one or more effector functions.
[0036] The "humanized" form of non-human (e.g., mouse) antibodies refers to chimeric antibodies containing a minimum amount of non-human immunoglobulin sequences. Most humanized antibodies are hypervariable region residues of human recipient immunoglobulins that are replaced with non-human (e.g., mouse, rat, rabbit, or non-human primate) hypervariable region residues (donor antibodies) with desired specificity, affinity, and function. In some embodiments, the framework region (FR) residues of human immunoglobulins are also replaced with non-human residues. Moreover, humanized antibodies may also include residues that are not present in the recipient antibody or the donor antibody. These modifications are to further optimize the performance of the antibody. Humanized antibodies generally include at least one, usually two variable regions, in which all or nearly all hypervariable loops correspond to those of non-human immunoglobulins, while FRs are completely or almost completely sequences of human immunoglobulins. Humanized antibodies may also include at least a portion of an immunoglobulin constant region (Fc, usually human immunoglobulin Fc). For details, see, e.g., Jones et al., 1986, Nature, 321:522-525; Riechmann et al., 1988, Nature, 332:323-329; and Presta, 1992, Curr Op Struct Bwl 2:593-596.
[0037] Intact antibodies can be divided into different "classes" based on the amino acid sequence of the heavy chain constant region. The five main classes are IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into different "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions of different classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known in the art.
[0038] In this article, although in most cases the amino acid substitution in the antibody is replaced by L-amino acids, it is not limited thereto. In some embodiments, one or more D-amino acids may be included in the antibody peptide chain. It is believed that peptides containing D-amino acids are more stable and less prone to degradation in the oral cavity, intestinal tract or plasma than peptides containing only L-amino acids.
[0039] The monoclonal antibodies used in the present invention can be produced by many methods. For example, the monoclonal antibodies used in the present invention can be obtained by hybridoma method using many species (including cells of mice, hamsters, rats and people) (see, for example, Kohler et al., 1975, Nature, 256:495), or obtained by recombinant DNA technology (see, for example, US 4,816,567), or separated from phage antibody libraries (see, for example, Clackson et al., 1991, Nature, 352:624-628; and Marks et al., 1991, Journal of Molecular Biology, 222:581-597).
[0040] The anti-HER2 antibody of the present invention is preferably an anti-human HER2 antibody. Preferably, the CDR1, CDR2 and / or CDR3 of the heavy chain and light chain in the anti-human HER2 antibody are the CDR1, CDR2 and / or CDR3 of the heavy chain and light chain of trastuzumab, respectively. The anti-human HER2 antibody can be a humanized antibody or a fully human antibody.
[0041] The anti-HER2 antibody used in the present invention is more preferably the antibody of US 5,821,337 Figure 1 The humanized antibody of the murine anti-human HER2 antibody 4D5 is shown in FIG.
[0042] The anti-HER2 antibody used in the present invention is particularly preferably trastuzumab, whose sequence has been disclosed, for example, in CN103319599A. The last Lys of the heavy chain of trastuzumab is easily deleted, but this deletion does not affect the biological activity, see Dick, LW et al., Biotechnol. Bioeng., 100: 1132-1143. The above-mentioned trastuzumab and its sequence or fragment with the last Lys of the heavy chain deleted belong to the trastuzumab described in the present invention.
[0043] As used herein, the term "cytotoxic drug" refers to a substance that inhibits or prevents the function of cells and / or causes cell destruction.
[0044] The antibody-drug conjugate of the present invention may be in the form of a pharmaceutically acceptable salt, or in the form of a stereoisomer, or in the form of a metabolite, or in the form of a solvate, and the salt, stereoisomer or metabolite may also be in the form of a solvate.
[0045] The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the compound and are biologically or otherwise desirable for use as a drug. In many cases, the antibody-drug conjugates of the present invention form acid addition salts and / or base addition salts by virtue of the presence of amino and / or carboxyl groups or similar groups therein.
[0046] Pharmaceutically acceptable acid addition salts may be salts formed with inorganic or organic acids. The inorganic acid includes, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. The organic acid includes, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid.
[0047] Pharmaceutically acceptable base addition salts may be salts formed with inorganic bases or organic bases. The salts formed with inorganic bases include, for example, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts and aluminum salts, and ammonium salts, potassium salts, sodium salts, calcium salts and magnesium salts are particularly preferred. The organic bases include, for example, primary amines, secondary amines and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, basic ion exchange resins, and the like. Specific examples of organic bases are isopropylamine, trimethylamine, diethylamine, N-ethylethylamine, tripropylamine and ethanolamine.
[0048] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In compounds with one or more asymmetric centers, racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers can be produced. Specific individual molecules can also exist as geometric isomers (cis / trans). Unless otherwise stated, when the stereochemistry of a disclosed compound is not clearly stated in the nomenclature or structure and has one or more asymmetric centers, it should be understood that all possible stereoisomers of the compound are represented.
[0049] The term "solvate" refers to a solvate formed by the association of one or more solvent molecules with an antibody-drug conjugate of any formula (I) or a pharmaceutically acceptable salt or isomer thereof. The term solvate includes hydrates (e.g., hemihydrates, monohydrates, dihydrates, trihydrates, tetrahydrates and the like).
[0050] The term "metabolite" refers to a substance that may be formed in vivo after administration through oxidation, reduction, hydrolysis, amidation, deamidation, esterification and / or enzymatic degradation.
[0051] In this article, the term "treatment" includes maintenance therapy. The term "maintenance therapy" refers to the continuation of effective single-agent chemotherapy after the patient has completed the number of chemotherapy cycles specified in the initial chemotherapy and achieved the maximum tumor remission effect. Generally speaking, the maintenance drug dose used in maintenance therapy is relatively small, so the adverse reactions are relatively mild.
[0052] In this article, the term "insensitive to HER2-targeted drug therapy or ineffective HER2-targeted drug therapy" means that the cancer is not effectively controlled during the treatment with HER2-targeted drugs or after the last treatment, the disease progresses or relapses, or the lesions are not reduced as expected (for example, the sum of the lesion diameters is less than 30% less than the sum of the baseline); or before treatment, it can be determined by a known evaluation method that the cancer belongs to a type that is insensitive to HER2-targeted drug therapy or ineffective HER2-targeted drug therapy. The cause and mechanism of the insensitivity or ineffectiveness of the treatment can be any cause and mechanism that occurs clinically or in preclinical trials, including that the cancer cells are resistant to HER2-targeted drugs, such as intrinsic resistance or acquired resistance, or that the cancer belongs to a type of HER2 low expression, etc. The known evaluation method may include, for example, a method for determining the drug resistance of cancer cells or performing immunohistochemistry (IHC) and / or fluorescence in situ hybridization (FISH) detection.
[0053] In this article, the term "resistance" includes "intrinsic resistance" and "acquired resistance". The former refers to the insensitivity of cancer cells to drugs at the beginning of treatment, and the latter refers to the insensitivity of cancer cells that are initially sensitive to drugs after repeated exposure to drugs during treatment. As an example, the following situations can be regarded as cells with intrinsic resistance: disease progression is found within 3 months after the selection of trastuzumab as first-line treatment for metastatic breast cancer or at the time of the first imaging assessment 8-12 weeks after treatment; or a recurrence event is diagnosed within 12 months after the selection of trastuzumab as adjuvant treatment for metastatic breast cancer, such as the appearance of new tumor lesions. As an example, the following situations can be regarded as cells with acquired resistance: after treatment with a regimen containing trastuzumab, the first imaging assessment shows that the disease is relieved or stable, but the disease progresses after the second or later line of treatment, such as an increase in the diameter of the tumor lesion (for example, an increase in the diameter of more than 20%); or a recurrence event is diagnosed after 12 months of adjuvant treatment with trastuzumab, such as the appearance of new tumor lesions.
[0054] Herein, methods for determining the HER2 expression level of a patient and related techniques are known in the art. For example, detection of HER2 includes but is not limited to detection of HER2 protein by IHC and detection of HER2 gene by FISH technology.
[0055] In this article, the term "HER2 low expression" generally refers to the HER2 expression level of IHC 1+, or IHC 2+ / FISH negative (i.e., IHC 2+ and FISH detection is negative at the same time) in clinical detection. The terms "HER2 high expression", "HER2 overexpression" and "HER2 positive" are used interchangeably, generally referring to the HER2 expression level of IHC 2+ / FISH positive (i.e., IHC2+ and FISH detection is positive at the same time), or IHC 3+ in clinical detection. When the IHC staining intensity is reported as a range, the term "HER2 low expression" herein includes IHC 0 to 1+ and IHC 1+ to 2+ in addition to IHC 1+, or IHC 2+ / FISH negative. The terms "HER2 high expression", "HER2 overexpression" and "HER2 positive" each include IHC 2+ to 3+ in addition to IHC 2+ / FISH positive, or IHC 3+. In this article, FISH-negative means that the FISH test results show that the HER2 gene is not amplified, and FISH-positive means that the FISH test results show that the HER2 gene is amplified.
[0056] As used herein, the term "progression of disease" or "disease progression" refers to an increase of at least 20% in the sum of the diameters of target lesions, with reference to the minimum value of the sum of the diameters of all target lesions in the entire study (this includes the baseline sum if it is the minimum value in the study), and an absolute increase of at least 5 mm in the sum of the diameters; or the appearance of one or more new lesions.
[0057] Therapeutic uses and treatments
[0058] In some embodiments, the present invention provides a use of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing in the preparation of a medicament for preventing and / or treating cancers that are insensitive to or ineffective against HER2-targeted drug therapy,
[0059]
[0060] in
[0061] A is a group obtained by removing n amino groups from an anti-HER2 antibody or an active fragment or variant thereof, preferably, A is a group obtained by removing n amino groups from trastuzumab or pertuzumab, and
[0062] n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.
[0063] In some embodiments, the present invention provides a conjugate of the above-mentioned formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing, which is used to prevent and / or treat cancers that are insensitive to or ineffective against HER2-targeted drug therapy.
[0064] In some embodiments, the present invention provides a method for preventing and / or treating cancer that is insensitive to or ineffective against HER2-targeted drug therapy, the method comprising administering to an individual in need thereof a therapeutically effective amount of a conjugate of the above-mentioned formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
[0065] In a preferred embodiment, the conjugate of formula (I) has the structure of the following formula (I-1):
[0066]
[0067] A1 is the group obtained by removing two amino groups from trastuzumab.
[0068] In a preferred embodiment, the cancer that is insensitive to or ineffective against HER2-targeted drug therapy includes, but is not limited to, HER2-positive cancer that is insensitive to or ineffective against HER2-targeted drug therapy.
[0069] In a preferred embodiment, the HER2-positive cancer that is insensitive to HER2-targeted drug therapy or ineffective for HER2-targeted drug therapy includes a HER2-positive cancer that is resistant to HER2-targeted drugs (such as intrinsic resistance or acquired resistance). Preferably, the cancer includes breast cancer (such as metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer) or gastric cancer (such as advanced gastric cancer or metastatic gastric cancer), etc.
[0070] In a preferred embodiment, the cancer that is insensitive to HER2-targeted drug therapy or ineffective for HER2-targeted drug therapy includes, but is not limited to, cancer with low HER2 expression. Preferably, the cancer includes breast cancer (such as metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer) or gastric cancer (such as advanced gastric cancer or metastatic gastric cancer) with low HER2 expression, etc. More preferably, the cancer with low HER2 expression is a cancer with an expression level of HER2 of IHC 0 to 1+, IHC 1+, IHC 1+ to 2+ in clinical detection, or a cancer with IHC2+ / FISH negative. More preferably, the cancer with low HER2 expression is a cancer with IHC 1+, or a cancer with IHC2+ / FISH negative.
[0071] In a preferred embodiment, the drug targeting HER2 includes: anti-HER2 antibody drugs, such as monoclonal antibodies, antibody drug conjugates (ADC) and bispecific antibodies, or HER2-targeting chemical drugs, such as lapatinib, neratinib, afatinib or varlitinib. Preferably, the drug targeting HER2 includes trastuzumab or pertuzumab or its biosimilars, such as ABP 980, GB221, MYL-1401O, CT-P6, EG12014, HD201, ONS-1050, PF-05280014, HD201, Ontruzant or HLX02, or includes trastuzumab or pertuzumab or its biosimilars as the targeting component of the antibody-drug conjugate, such as the antibody-cytotoxic drug conjugate coupled with the targeting component and DM1, DM4, MMAE or MMAF, such as T-DM1.
[0072] In a preferred embodiment, the cancer that is insensitive to or ineffective against HER2-targeted drug therapy is breast cancer that is insensitive to or ineffective against trastuzumab and / or T-DM1 therapy, preferably HER2-positive breast cancer that is insensitive to or ineffective against trastuzumab and / or T-DM1 therapy.
[0073] In a preferred embodiment, the cancer that is insensitive to HER2-targeted drug therapy or ineffective for HER2-targeted drug therapy is breast cancer that is resistant to trastuzumab and / or T-DM1 therapy (such as intrinsic resistance or acquired resistance), preferably HER2-positive breast cancer that is resistant to trastuzumab and / or T-DM1 therapy (such as intrinsic resistance or acquired resistance).
[0074] In a preferred embodiment, the cancer that is insensitive to or ineffective against HER2-targeted drug therapy is HER2-low expressing breast cancer, preferably HER2-low expressing breast cancer that is insensitive to or ineffective against trastuzumab and / or T-DM1 therapy.
[0075] In a preferred embodiment, the phrase "cancer insensitive to HER2-targeted drug therapy or ineffective HER2-targeted drug therapy" used herein includes treatment with trastuzumab and / or treatment with T-DM1. Preferably, the treatment is selected from:
[0076] (1) Use of trastuzumab to treat breast cancer, including an initial loading dose of 4 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 2 mg / kg body weight by intravenous infusion every week, until disease progression; or, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks, until disease progression;
[0077] (2) Adjuvant treatment of breast cancer with trastuzumab, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks for 52 weeks; or, including an initial loading dose of 4 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 2 mg / kg body weight by intravenous infusion every week for 12 weeks (combined with paclitaxel or docetaxel) or 18 weeks (combined with docetaxel / carboplatin), followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks for 52 weeks;
[0078] (3) Treatment of gastric cancer with trastuzumab, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks until disease progression; or
[0079] (4) T-DM1 is used to treat breast cancer, including intravenous infusion of 3.6 mg / kg body weight once every three weeks, and maintenance treatment until disease progression or unacceptable toxicity.
[0080] In a preferred embodiment, the prevention and / or treatment comprises administering to the patient a therapeutically effective amount of a conjugate of formula (I) (preferably a conjugate of formula (I-1)), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing, preferably at a dose of 0.1-15 mg / kg body weight, more preferably at a dose of 0.5-10 mg / kg body weight, and most preferably at a dose of 1-8 mg / kg body weight.
[0081] In a preferred embodiment, the prevention and / or treatment also includes the step of assessing whether the patient's cancer is insensitive to the drug therapy targeting HER2 or the drug therapy targeting HER2 is insensitive to the ineffective treatment before administration. Preferably, the assessment includes assessing whether the patient's cancer has drug resistance (such as intrinsic drug resistance and / or acquired drug resistance) to the drug targeting HER2, or assessing whether the patient's cancer belongs to a cancer with low expression of HER2. The assessment can be carried out by methods known in the art.
[0082] In a preferred embodiment, the prevention and / or treatment comprises the following steps:
[0083] (1) treating HER2-positive cancer patients with a drug targeting HER2 and monitoring whether the patients have resistance to the drug targeting HER2; and
[0084] (2) administering a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate thereof to a HER2-positive cancer patient who is resistant to a drug targeting HER2.
[0085] Preferably, the drug resistance is monitored by imaging detection of the tumor (such as X-ray, CT scan or MRI), or by tumor biomarker detection.
[0086] Preferably, the drug targeting HER2 includes trastuzumab or T-DM1.
[0087] Preferably, the HER2-positive cancer includes breast cancer (such as metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer) or gastric cancer (such as advanced gastric cancer or metastatic gastric cancer) and the like.
[0088] Preferably, the conjugate of formula (I) is a conjugate of formula (I-1).
[0089] In a preferred embodiment, the prevention and / or treatment comprises the following steps:
[0090] (1) Treating patients with HER2-positive cancer with drugs that target HER2 and monitoring cancer progression; and
[0091] (2) When disease progression occurs, administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
[0092] Preferably, the disease progression of the cancer is monitored by imaging detection of the tumor (such as X-ray, CT scan or MRI), or by detection of tumor biomarkers.
[0093] Preferably, monitoring the disease progression of cancer comprises comparing the tumor at a second time point with the tumor at a first time point, wherein the first time point is before or after treatment with a drug targeting HER2, and the second time point is after the first time point.
[0094] Preferably, the drug targeting HER2 includes trastuzumab or T-DM1.
[0095] Preferably, the HER2-positive cancer includes breast cancer (such as metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer) or gastric cancer (such as advanced gastric cancer or metastatic gastric cancer) and the like.
[0096] Preferably, the conjugate of formula (I) is a conjugate of formula (I-1).
[0097] In a preferred embodiment, the prevention and / or treatment comprises the following steps:
[0098] (1) detecting HER2 expression levels in cancer patients; and
[0099] (2) When HER2 expression is low, administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
[0100] Preferably, the drug targeting HER2 includes trastuzumab or T-DM1.
[0101] Preferably, the cancer includes breast cancer (such as metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer) or gastric cancer (such as advanced gastric cancer or metastatic gastric cancer) and the like.
[0102] Preferably, the conjugate of formula (I) is a conjugate of formula (I-1). Example
[0103] The present invention will be further illustrated in the following examples. These examples are only used to illustrate the present invention, but are not intended to limit the present invention in any way.
[0104] In Examples 1 and 2, the anti-tumor effect of the conjugate of formula (I-1) on mice bearing tumors subcutaneously transplanted with human tumor cells or human tumor tissues was evaluated. Specifically, the conjugate of formula (I-1) was injected into the tail vein once to mice bearing tumors subcutaneously transplanted with human breast cancer cell line JIMT-1 (HER2 positive breast cancer cell line, trastuzumab resistant cell line, M Barok et al., Breast Cancer Res. April 21, 2011. 13 (2): R46; Marvi Jumppanen, Basal Cytokeratins and HER-2 Oncogene in Breast Cancer, 2007) and PDX human breast cancer tumor xenograft mouse animal model BR0438 (HER2 low expression, IHC 1+ to 2+). The tumor volume and animal body weight changes were measured twice a week, and the efficacy (tumor inhibition efficacy) of the conjugate of formula (I-1) on tumor-bearing mice was calculated.
[0105] Test drug
[0106] Take appropriate amount of trastuzumab (naked antibody, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.), T-DM1 ( Roche Pharmaceuticals) and the antibody-drug conjugate of formula (I-1) (Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.), respectively, were prepared into a mother solution of a certain concentration with sterile ultrapure water, gently shaken, packaged, and stored at -20°C. When used, it was diluted with physiological saline according to the dose to obtain a treatment group solution. At the same time, a blank control group was set up (the difference between the blank control group and the antibody-drug conjugate group of formula (I-1) is that it does not contain the active pharmaceutical ingredient).
[0107] Experimental animals and cell lines
[0108] NOD / SCID mice (Beijing Huafukang Biotechnology Co., Ltd.).
[0109] Breast cancer cell line JIMT-1 (AddexBio), PDX human breast cancer tumor xenograft mouse animal model BR0438 (Crown Biotechnology).
[0110] Experimental grouping and evaluation methods
[0111] The tumor volume was 100-200 mm2 and the random grouping (the number of groups was determined according to the number of samples) was selected. 3 The tumor-bearing mice were divided into 8 groups. The administration volume was 10 mL / kg body weight, and the administration method was a single tail vein injection. The mice were observed for 4 weeks after administration, and the tumor diameter was measured with a vernier caliper twice a week, and the tumor volume was calculated according to the following formula: V = 0.5a × b 2 , where a and b represent the long diameter and short diameter of the tumor, respectively. Animal deaths were observed and recorded every day.
[0112] The tumor growth inhibition rate TGI (%) was calculated using the following formula to evaluate the tumor inhibition efficacy of antibody-drug conjugates:
[0113] TGI (%) = [1-(V T末 -V T始 ) / (V C末 -V C始 )]*100%
[0114] Where V T末 : Mean tumor volume at the end of the treatment group experiment;
[0115] V T始 : Mean tumor volume at the start of drug administration in the treatment group;
[0116] V C末 : Mean tumor volume of blank control group at the end of the experiment;
[0117] V C始 : Mean tumor volume of blank control group at the beginning of drug administration.
[0118] Example 1. Human breast cancer JIMT-1 model
[0119] Experimental methods:
[0120] JIMT-1 cells were cultured in DMEM containing 10% fetal bovine serum at 37°C and 5% CO2. JIMT-1 cells in the exponential growth phase were collected, resuspended in PBS to a suitable concentration, and inoculated subcutaneously in female NOD / SCID mice to establish a breast cancer model. When the tumor grew to an average volume of about 122 mm 3 The mice were randomly divided into groups according to the tumor volume. After grouping, blank control, T-DM1, naked trastuzumab, low, medium and high doses of the antibody-drug conjugate of formula (I-1) were injected into the tail vein once. The tumor volume and body weight of the mice were observed and measured regularly after injection. The specific results are shown in Tables 1-1, 1-2 and Figure 1-2 .
[0121] Experimental conclusion:
[0122] The human breast cancer cell line JIMT-1 used in this example is a HER2-positive trastuzumab-resistant cell line (MBarok et al., Breast Cancer Res. 2011 April 21; 13(2): R46.). This cell line was used to construct a human breast cancer subcutaneous transplant tumor model, and the anti-tumor efficacy of the antibody-drug conjugate of formula (I-1), naked trastuzumab, and T-DM1 was evaluated and compared.
[0123] Table 1-1. Human breast cancer JIMT-1 model
[0124]
[0125] *P values less than 0.05 indicated significant differences.
[0126] As can be seen from Table 1-1, there is no significant difference in the inhibition of tumor growth between the naked trastuzumab group and the blank control group, indicating that naked trastuzumab has no inhibitory effect on tumor growth in trastuzumab-resistant JIMT-1 breast cancer transplanted tumor model mice; T-DM1 has only a low inhibitory effect on tumor growth, while low, medium and high doses of the antibody-drug conjugate of formula (I-1) all significantly and dose-dependently inhibit tumor growth.
[0127] The comparison of the therapeutic effects of the antibody-drug conjugate of formula (I-1) and T-DM1 is shown in Table 1-2.
[0128] Table 1-2. Human breast cancer JIMT-1 model
[0129]
[0130] *P values less than 0.05 indicated significant differences.
[0131] As shown in Table 1-2, compared with T-DM1, the anti-tumor efficacy of medium and high doses of the antibody-drug conjugate of formula (I-1) was significantly better than that of T-DM1 (P < 0.001); there was no statistically significant difference between the low-dose group and T-DM1 in inhibiting tumor growth (P > 0.05), but the two indicators of tumor volume and tumor growth inhibition rate were also significantly better than T-DM1.
[0132] Depend on Figure 2 It can be seen that there was no animal death or significant animal weight loss in all treatment groups shown in Tables 1-1 and 1-2 during the observation period, and no obvious drug toxicity was shown. During the treatment period, the mice tolerated the evaluated drugs well.
[0133] Example 2. Breast cancer tumor xenograft model BR0438
[0134] Experimental methods:
[0135] BR0438 is a xenograft model established from a breast cancer tumor from a 53-year-old female patient. The patient was pathologically diagnosed with invasive ductal carcinoma of the breast and low HER2 expression (IHC 1+ to 2+). NOD / SCID mice were subcutaneously inoculated with BR0438 tumors to establish a human breast cancer subcutaneous transplant tumor model. When the tumor grew to an average volume of approximately 173mm 3 The mice were randomly divided into groups according to the tumor volume, and the blank control, T-DM1, naked trastuzumab, low-dose and high-dose antibody-drug conjugate of formula (I-1) were injected into the tail vein once. The tumor volume and body weight of the mice were observed and measured regularly after injection. The specific results are shown in Table 2 and Figure 3-4 .
[0136] Table 2: PDX breast cancer xenograft model BR0438
[0137]
[0138] *P values less than 0.05 indicated significant differences.
[0139] Experimental conclusion:
[0140] As shown in Table 2, there was no significant difference in the inhibition of tumor growth between the naked trastuzumab group and the T-DM1 group and the blank control group (P>0.05), indicating that naked trastuzumab and T-DM1 had no inhibitory effect on tumor growth in the BR0438 breast cancer transplanted tumor model mice, while the antibody-drug conjugate of formula (I-1) in the high and low dose groups significantly inhibited tumor growth in a dose-dependent manner. Figure 4 It can be seen that there was no animal death or significant animal weight loss in all treatment groups during the observation period, and no obvious drug toxicity was shown. During the treatment period, the mice tolerated the evaluated drugs well.
[0141] Trastuzumab and T-DM1 do not show therapeutic effects on breast cancer tumors with low HER2 expression, while the antibody-drug conjugate of formula (I-1) of the present invention has a significant inhibitory effect and is expected to be used for patients with HER2 low-expressing tumors who are ineffective against trastuzumab and T-DM1 treatment.
[0142] In summary, the antibody-drug conjugate of formula (I) of the present invention is expected to treat patients who are insensitive to HER2-targeting drug therapy such as trastuzumab and / or T-DM1, or who are ineffective against HER2-targeting drug therapy such as trastuzumab and / or T-DM1, such as breast cancer patients with drug resistance or low HER2 expression, and is expected to bring clinical benefits to more patients.
[0143] Although the present invention is described by the above specific embodiments, it should be understood that it should not be construed as being limited thereto. The present invention covers the general aspects disclosed above, and those skilled in the art may make various modifications or change the various details of the present invention without departing from the spirit and scope of the present invention. Therefore, this specification is for illustrative purposes only, not for limiting purposes.
Claims
1. Use of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing in the preparation of a drug for preventing and / or treating cancer that is insensitive to or ineffective against HER2-targeting drug therapy, in A is a group obtained by removing n amino groups from an anti-HER2 antibody or an active fragment or variant thereof, and n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.
2. The use as claimed in claim 1, wherein A is a group obtained by removing n amino groups from trastuzumab or pertuzumab.
3. The use according to claim 1 or 2, wherein the conjugate of formula (I) has the structure of the following formula (I-1), A1 is the group obtained by removing two amino groups from trastuzumab.
4. The use according to any one of claims 1 to 3, wherein the cancer comprises a HER2-positive cancer that is insensitive to or ineffective against HER2-targeted drug therapy.
5. The use according to claim 4, wherein the HER2-positive cancer comprises a HER2-positive cancer that is resistant to a drug targeting HER2.
6. The use according to claim 5, wherein the HER2-positive cancer includes a HER2-positive cancer having intrinsic resistance or acquired resistance to a drug targeting HER2.
7. The use according to claim 6, wherein The cancer includes breast cancer or gastric cancer.
8. The use according to claim 7, wherein The cancer includes metastatic breast cancer, locally advanced breast cancer, recurrent breast cancer, advanced gastric cancer or metastatic gastric cancer.
9. The use according to claim 1 or 2, wherein the cancer comprises a cancer with low HER2 expression.
10. The use according to claim 9, wherein the patient is a breast cancer or a gastric cancer with low HER2 expression.
11. The use according to claim 10, wherein the cancer comprises metastatic breast cancer with low HER2 expression, locally advanced breast cancer with low HER2 expression, recurrent breast cancer with low HER2 expression, advanced gastric cancer with low HER2 expression or metastatic gastric cancer with low HER2 expression.
12. The use according to any one of claims 9 to 11, wherein the cancer with low HER2 expression is a cancer whose HER2 expression level in clinical detection is IHC 0 to 1+, IHC 1+, IHC 1+ to 2+, or an IHC2+ / FISH-negative cancer.
13. The use according to claim 12, wherein the cancer with low HER2 expression is a cancer whose HER2 expression level in clinical detection is IHC 1+, or IHC2+ / FISH negative.
14. The use according to any one of claims 9 to 11, wherein the cancer with low HER2 expression is a cancer whose HER2 expression level in clinical detection is IHC 0 to 1+, or IHC 1+ to 2+.
15. The use according to any one of claims 1 to 14, wherein the drug targeting HER2 comprises: Anti-HER2 antibody drugs, or drugs targeting HER2.
16. The use according to claim 15, wherein the anti-HER2 antibody drug is a monoclonal antibody, an antibody-drug conjugate (ADC) or a bispecific antibody; and / or the chemical drug targeting HER2 is lapatinib, neratinib, afatinib or varlitinib.
17. The use according to claim 15 or 16, wherein the drug targeting HER2 comprises trastuzumab or pertuzumab or a biosimilar thereof, or comprises an antibody-drug conjugate having trastuzumab or pertuzumab or a biosimilar thereof as a targeting component.
18. The use according to claim 17, wherein the trastuzumab or pertuzumab or a biosimilar thereof is ABP 980, GB221, MYL-1401O, CT-P6, EG12014, HD201, ONS-1050, PF-05280014, HD201, Ontruzant or HLX02; the antibody-drug conjugate with trastuzumab or pertuzumab or a biosimilar thereof as a targeting component is an antibody-cytotoxic drug conjugate coupled to DM1, DM4, MMAE or MMAF as a targeting component.
19. The use according to claim 18, wherein the antibody-drug conjugate with trastuzumab or pertuzumab or a biosimilar thereof as a targeting component is T-DM1.
20. The use according to any one of claims 1 to 19, wherein the drug therapy targeting HER2 comprises drug therapy with trastuzumab and / or drug therapy with T-DM1.
21. The use according to claim 20, The treatment is selected from: (1) Use of trastuzumab to treat breast cancer, including an initial loading dose of 4 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 2 mg / kg body weight by intravenous infusion every week, until disease progression; or, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks, until disease progression; (2) Adjuvant treatment of breast cancer with trastuzumab, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks for 52 weeks; or, including an initial loading dose of 4 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 2 mg / kg body weight by intravenous infusion every week for 12 weeks when combined with paclitaxel or docetaxel, and for 18 weeks when combined with docetaxel / carboplatin, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks for 52 weeks; (3) Treatment of gastric cancer with trastuzumab, including an initial loading dose of 8 mg / kg body weight by intravenous infusion, followed by a maintenance dose of 6 mg / kg body weight by intravenous infusion every three weeks until disease progression; or (4) T-DM1 is used to treat breast cancer, including intravenous infusion of 3.6 mg / kg body weight once every three weeks, and maintenance treatment until disease progression or unacceptable toxicity.
22. The use according to any one of claims 1 to 21, wherein the prevention and / or treatment comprises administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
23. The use of claim 22, wherein the prevention and / or treatment comprises administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing at a dose of 0.1-15 mg / kg body weight.
24. The use of claim 23, wherein the prevention and / or treatment comprises administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing at a dose of 1-8 mg / kg body weight.
25. The use according to any one of claims 1 to 24, wherein the prevention and / or treatment further comprises a step of evaluating whether the patient's cancer is insensitive to HER2-targeted drug therapy or HER2-targeted drug therapy is ineffective before administration.
26. The use of claim 25, wherein the evaluation comprises evaluating whether the patient's cancer is resistant to a drug targeting HER2, or evaluating whether the patient's cancer is a cancer with low HER2 expression.
27. The use of claim 26, wherein the assessment comprises assessing whether the patient's cancer has intrinsic resistance and / or acquired resistance to a drug targeting HER2, or assessing whether the patient's cancer is a cancer with low HER2 expression.
28. The use according to any one of claims 1 to 27, wherein the prevention and / or treatment comprises the following steps: (1) treating HER2-positive cancer patients with a drug targeting HER2 and monitoring whether the patients have resistance to the drug targeting HER2; and (2) administering a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate thereof to a HER2-positive cancer patient who is resistant to a drug targeting HER2.
29. The use according to claim 28, wherein the drug resistance is monitored by imaging detection of the tumor, or by detection of tumor biomarkers.
30. The use according to claim 29, wherein the imaging test is X-ray, CT scan or MRI.
31. The use according to claim 28, wherein the drug targeting HER2 comprises trastuzumab or T-DM1.
32. The use of claim 28, wherein the HER2-positive cancer comprises breast cancer or gastric cancer.
33. The use of claim 32, wherein the HER2-positive cancer comprises metastatic breast cancer, locally advanced breast cancer, recurrent breast cancer, advanced gastric cancer or metastatic gastric cancer.
34. The use according to any one of claims 1 to 33, wherein the prevention and / or treatment comprises the following steps: (1) Treating patients with HER2-positive cancer with drugs that target HER2 and monitoring cancer progression; and (2) When disease progression occurs, administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
35. The use according to claim 34, wherein: The disease progression of the cancer is monitored by imaging detection of the tumor or by detecting tumor biomarkers.
36. The use according to claim 35, wherein: The imaging test is X-ray, CT scan or MRI.
37. The use according to claim 34, wherein: Monitoring the disease progression of cancer includes comparing the tumor at a second time point with the tumor at a first time point, wherein the first time point is before or after treatment with a drug targeting HER2, and the second time point is after the first time point.
38. The use according to claim 34, wherein: The drugs targeting HER2 include trastuzumab or T-DM1.
39. The use according to claim 34, wherein: The HER2-positive cancer includes breast cancer or gastric cancer.
40. The use according to claim 39, wherein: The HER2-positive cancers include metastatic breast cancer, locally advanced breast cancer or recurrent breast cancer, advanced gastric cancer or metastatic gastric cancer.
41. The use according to any one of claims 1 to 40, wherein the prevention and / or treatment comprises the following steps: (1) detecting HER2 expression levels in cancer patients; and (2) When HER2 expression is low, administering to the patient a therapeutically effective amount of a conjugate of formula (I), a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
42. The use according to claim 41, wherein: The drugs targeting HER2 include trastuzumab or T-DM1.
43. The use according to claim 41, wherein: The cancer includes breast cancer or gastric cancer.
44. The use according to claim 43, wherein: The cancer includes metastatic breast cancer, locally advanced breast cancer, recurrent breast cancer, advanced gastric cancer or metastatic gastric cancer.
45. A method for preventing and / or treating cancer that is insensitive to or ineffective against HER2-targeted drug therapy, the method comprising administering to an individual in need thereof a therapeutically effective amount of a conjugate of formula (I) as defined in claim 1, a pharmaceutically acceptable salt, stereoisomer or metabolite thereof, or a solvate of the foregoing.
46. The method of claim 44, wherein the conjugate is a conjugate of formula (I-1) as defined in claim 3, the cancer that is insensitive to or ineffective against HER2-targeted drug therapy is as defined in any one of claims 4-21, and / or the prevention and / or treatment is as defined in any one of claims 22-43.
